Merck & Co.'s experimental anti-platelet drug vorapaxar reduces the risk of heart attacks but increases the risk of significant bleeding.
The latest studies have raised questions whether the company will seek approval for the drug from the U.S. Food and Drug Administration.
Heart Attack
Heart attack is the death of the heart muscle due to loss of blood supply. Heart disease is the leading cause of death in the United States. Other names for heart attack include acute myocardial infarction, coronary thrombosis, and coronary occlusion.
Advertisement
From January 2011 a safety committee overseeing the 26,449-patient study had questioned its efficacy as they found that the new type of anti-platelet drug was not appropriate for patients who had suffered a stroke, due to bleeding risk.
Source: Medindia
Heart Attack- Lifestyle risks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to avoid heart attack are listed.
Advertisement
 StrokeStroke can cause permanent disability and it is important to recognize its early warning signs to stop its progress. Early warning signs of stroke include sudden weakness of facial muscles. | Advertisement
|
How to Deal with a Stroke
Stroke is a brain attack, which occurs when the blood supply to the brain is interrupted. It affects all age groups; according to the WHO, 15 million people are affected by stroke annually.
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.